Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshio Okano

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Internal Medicine (Tokyo, Japan)|December 22, 2011
Acute myeloid leukemia with myelodysplasia-related changes mimicking acute promyelocytic leukemiaHisanori Machida, Tsutomu Shinohara, Yoshihito Iwahara, et al.
Medicine|July 15, 2025
Successful pembrolizumab treatment in a patient with ALK-positive lung adenocarcinoma: A case report and literature reviewYugo Matsumura, Seiya Ichihara, Kaori Nii, et al.
Internal Medicine (Tokyo, Japan)|November 3, 2015
Primary Gingival Tuberculosis Diagnosed Based on Genetic IdentificationYoshio Okano, Shiomi Yoshida, Tsutomu Shinohara, et al.
Thoracic Cancer|August 23, 2023
A randomized phase III study of docetaxel alone versus docetaxel plus S-1 in patients with previously treated non-small cell lung cancer: JMTO LC09-01Shinji Atagi, Takashi Daimon, Kyoichi Okishio, et al.
Thoracic Cancer|December 21, 2021
Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patientYoshio Okano, Michihiro Kunishige, Yoshihiro Kondo, et al.
Cancer Reports (Hoboken, N.J.)|November 24, 2021
Complete and durable response of pulmonary large-cell neuroendocrine carcinoma to pembrolizumabNaoki Kadota, Nobuo Hatakeyama, Hiroyuki Hino, et al.
Internal Medicine (Tokyo, Japan)|July 16, 2011
Immunoglobulin D-lambda type multiple myeloma presenting with FDG-PET/CT negative bone marrow involvementHisanori Machida, Tsutomu Shinohara, Hiroyuki Hino, et al.
Respiratory Investigation|January 13, 2018
Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancerHisatsugu Goto, Yoshio Okano, Hisanori Machida, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2011
A multi-institutional phase II trial of consolidation S-1 after concurrent chemoradiotherapy with cisplatin and vinorelbine for locally advanced non-small cell lung cancerTomoya Kawaguchi, Minoru Takada, Masahiko Ando, et al.
Cancer Reports (Hoboken, N.J.)|July 7, 2025
First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case ReportYugo Matsumura, Seiya Ichihara, Kaori Nii, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Internal Medicine (Tokyo, Japan)|December 22, 2011
Acute myeloid leukemia with myelodysplasia-related changes mimicking acute promyelocytic leukemiaHisanori Machida, Tsutomu Shinohara, Yoshihito Iwahara, et al.
Medicine|July 15, 2025
Successful pembrolizumab treatment in a patient with ALK-positive lung adenocarcinoma: A case report and literature reviewYugo Matsumura, Seiya Ichihara, Kaori Nii, et al.
Internal Medicine (Tokyo, Japan)|November 3, 2015
Primary Gingival Tuberculosis Diagnosed Based on Genetic IdentificationYoshio Okano, Shiomi Yoshida, Tsutomu Shinohara, et al.
Thoracic Cancer|August 23, 2023
A randomized phase III study of docetaxel alone versus docetaxel plus S-1 in patients with previously treated non-small cell lung cancer: JMTO LC09-01Shinji Atagi, Takashi Daimon, Kyoichi Okishio, et al.
Thoracic Cancer|December 21, 2021
Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patientYoshio Okano, Michihiro Kunishige, Yoshihiro Kondo, et al.
Cancer Reports (Hoboken, N.J.)|November 24, 2021
Complete and durable response of pulmonary large-cell neuroendocrine carcinoma to pembrolizumabNaoki Kadota, Nobuo Hatakeyama, Hiroyuki Hino, et al.
Internal Medicine (Tokyo, Japan)|July 16, 2011
Immunoglobulin D-lambda type multiple myeloma presenting with FDG-PET/CT negative bone marrow involvementHisanori Machida, Tsutomu Shinohara, Hiroyuki Hino, et al.
Respiratory Investigation|January 13, 2018
Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancerHisatsugu Goto, Yoshio Okano, Hisanori Machida, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2011
A multi-institutional phase II trial of consolidation S-1 after concurrent chemoradiotherapy with cisplatin and vinorelbine for locally advanced non-small cell lung cancerTomoya Kawaguchi, Minoru Takada, Masahiko Ando, et al.
Cancer Reports (Hoboken, N.J.)|July 7, 2025
First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case ReportYugo Matsumura, Seiya Ichihara, Kaori Nii, et al.
Pageof 4